Akebia Therapeutics

AKEBIA THERAPEUTICS INC

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Trade tensions weigh on oil demand

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AKBA

BHIL

ELEV

OPTN

WINT

Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase

Stock Movers

Pre-Market Outlook

Movers

EFXT

GHRS

MAZE

MCHP

TIGR

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

Five,Below,Now,Open,-,Closeup,Of,Sign,On,Building

AGMH

DEVS

FIVE

IOBT

MHUA

RVSB

VRPX

ZCAR

Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

Akebia Therapeutics Inc

AKBANK T/A/S GDR 144A by Akbank Turk Anonim Sirketi

Akbank TAS

AKBANK T/A/S S/ADR by Akbank Turk Anonim Sirketi

Offerings

Press Releases

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Akebia Therapeutics Announces Multiple Positive Business Updates

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Abivax

Altimmune

AnaptysBio

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Erasca

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Humacyte

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Keros Therapeutics

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Oruka Therapeutics

Precigen

Regenxbio

Relay Therapeutics

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sage Therapeutics

Sana Biotechnology

Stoke Therapeutics

Savara

Tourmaline Bio

Tyra Biosciences

Upstream Bio

Valneva

Verve Therapeutics

Piper Sandler

HC Wainwright & Co.

BTIG

Mizuho

Comments

Akebia Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga